Blueprint Medicines (BPMC) News Today $93.08 -2.19 (-2.30%) Closing price 04:00 PM EasternExtended Trading$93.11 +0.03 (+0.03%) As of 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Emerald Advisers LLC Increases Stake in Blueprint Medicines Co. (NASDAQ:BPMC)Emerald Advisers LLC grew its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 10.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 416,866 shares of the biotechnology company's stock after buying an additional 41,000 shMarch 24 at 7:08 AM | marketbeat.comFox Run Management L.L.C. Grows Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC)Fox Run Management L.L.C. boosted its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 262.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,264 shares of the biotechnology compMarch 24 at 5:51 AM | marketbeat.comKnights of Columbus Asset Advisors LLC Invests $1.10 Million in Blueprint Medicines Co. (NASDAQ:BPMC)Knights of Columbus Asset Advisors LLC purchased a new position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 12,652 shares of the bMarch 24 at 5:43 AM | marketbeat.com3,084 Shares in Blueprint Medicines Co. (NASDAQ:BPMC) Bought by Magnetar Financial LLCMagnetar Financial LLC purchased a new position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 3,084 shares of the biotechnology compaMarch 24 at 4:30 AM | marketbeat.com5,950 Shares in Blueprint Medicines Co. (NASDAQ:BPMC) Bought by Cibc World Markets CorpCibc World Markets Corp bought a new position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 5,950 shares of the biotechnology company's stock, valued at aMarch 23 at 3:52 AM | marketbeat.comProficio Capital Partners LLC Makes New $1.01 Million Investment in Blueprint Medicines Co. (NASDAQ:BPMC)Proficio Capital Partners LLC bought a new position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 11,600 shares of the biotechnology coMarch 22 at 3:16 AM | marketbeat.comBlueprint Medicines (NASDAQ:BPMC) Now Covered by Morgan StanleyMarch 22 at 1:50 AM | americanbankingnews.comBlueprint Medicines’ SWOT analysis: stock poised for growth amid challengesMarch 21, 2025 | investing.comBlueprint Medicines (NASDAQ:BPMC) Coverage Initiated by Analysts at Morgan StanleyMorgan Stanley began coverage on Blueprint Medicines in a report on Thursday. They set an "equal weight" rating and a $100.00 price objective on the stock.March 21, 2025 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Shares Purchased by Intech Investment Management LLCIntech Investment Management LLC raised its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 70.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 31,571 shares of the biotechnology company's stock after buyingMarch 21, 2025 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Shares Acquired by Swiss National BankSwiss National Bank increased its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 7.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 124,600 shares of the biotechnology company'March 21, 2025 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) have received an average rating of "Moderate Buy" from the twenty-three analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a hold rMarch 21, 2025 | marketbeat.comBlueprint Medicines assumed with an Equal Weight at Morgan StanleyMarch 20, 2025 | markets.businessinsider.comWolfe Research Initiates Coverage on Blueprint Medicines (NASDAQ:BPMC)March 20, 2025 | americanbankingnews.comWolfe Research Begins Coverage on Blueprint Medicines (NASDAQ:BPMC)Wolfe Research started coverage on Blueprint Medicines in a report on Tuesday. They issued an "outperform" rating for the company.March 19, 2025 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Victory Capital Management Inc.Victory Capital Management Inc. trimmed its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 91.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,023 shares of the biMarch 19, 2025 | marketbeat.comWolfe Research starts Blueprint Medicines at Outperform on bullish Ayvakit viewMarch 18, 2025 | msn.comBlueprint Medicines initiated with an Outperform at Wolfe ResearchMarch 18, 2025 | markets.businessinsider.comBlueprint Medicines (NASDAQ:BPMC) Now Covered by Analysts at Jefferies Financial GroupJefferies Financial Group started coverage on Blueprint Medicines in a report on Monday. They issued a "buy" rating and a $135.00 price objective for the company.March 18, 2025 | marketbeat.comWilliam Blair Investment Management LLC Purchases 269,896 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)William Blair Investment Management LLC raised its holdings in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 16.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,944,695 shares of the biotechnology company's stock aMarch 18, 2025 | marketbeat.comBlueprint Medicines (NASDAQ:BPMC) Now Covered by Jefferies Financial GroupMarch 18, 2025 | americanbankingnews.comJefferies Initiates Coverage of Blueprint Medicines (BPMC) with Buy RecommendationMarch 17, 2025 | msn.comPiper Sandler Remains a Hold on Blueprint Medicines (BPMC)March 17, 2025 | markets.businessinsider.comBlueprint Medicines initiated with a Buy at JefferiesMarch 17, 2025 | markets.businessinsider.com241,966 Shares in Blueprint Medicines Co. (NASDAQ:BPMC) Purchased by Raymond James Financial Inc.Raymond James Financial Inc. purchased a new position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 241,966 shares of the biotechnology companyMarch 17, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Boosts Stake in Blueprint Medicines Co. (NASDAQ:BPMC)Connor Clark & Lunn Investment Management Ltd. raised its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 2,680.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 142,717 shares of the biotechnology company's stock after buyMarch 16, 2025 | marketbeat.comBlueprint Medicines (NASDAQ:BPMC) Shares Down 1.6% - Should You Sell?March 16, 2025 | americanbankingnews.comBlueprint Medicines (NASDAQ:BPMC) Stock Price Down 1.6% - Time to Sell?Blueprint Medicines (NASDAQ:BPMC) Trading Down 1.6% - Time to Sell?March 15, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Purchases 7,165 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)Charles Schwab Investment Management Inc. boosted its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 1.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 604,397 shares of the bioMarch 14, 2025 | marketbeat.comWealthfront Advisers LLC Buys New Position in Blueprint Medicines Co. (NASDAQ:BPMC)Wealthfront Advisers LLC purchased a new stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 115,817 shares of the biotechnology company's stock, valued atMarch 12, 2025 | marketbeat.comEdgestream Partners L.P. Sells 35,728 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)Edgestream Partners L.P. cut its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 63.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,395 shares of the biotechMarch 11, 2025 | marketbeat.comEssex Investment Management Co. LLC Buys 10,275 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)Essex Investment Management Co. LLC increased its stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 29.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 45,736 shares of the biotechnology company's stock afMarch 10, 2025 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Stock Holdings Lifted by Bank of New York Mellon CorpBank of New York Mellon Corp lifted its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 2.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 303,432 shares of the biotechnology company's stock after acquiringMarch 10, 2025 | marketbeat.comScotiabank Initiates Coverage of Blueprint Medicines (BPMC) with Sector Outperform RecommendationMarch 8, 2025 | msn.comScotiabank Begins Coverage on Blueprint Medicines (NASDAQ:BPMC)Scotiabank began coverage on shares of Blueprint Medicines in a research report on Friday. They issued a "sector outperform" rating and a $150.00 target price for the company.March 8, 2025 | marketbeat.comZacks Research Has Positive Estimate for BPMC Q1 EarningsBlueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Analysts at Zacks Research raised their Q1 2025 earnings estimates for Blueprint Medicines in a research note issued to investors on Wednesday, March 5th. Zacks Research analyst A. Chakraborty now forecasts that the biotechnology company willMarch 8, 2025 | marketbeat.comAigen Investment Management LP Acquires Shares of 4,485 Blueprint Medicines Co. (NASDAQ:BPMC)Aigen Investment Management LP bought a new stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 4,485 shares of the biotechnology coMarch 8, 2025 | marketbeat.comProficio Capital Partners LLC Purchases Shares of 11,600 Blueprint Medicines Co. (NASDAQ:BPMC)Proficio Capital Partners LLC bought a new stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 11,600 shares of the biotechnology company's stMarch 8, 2025 | marketbeat.comBlueprint Medicines initiated with an Outperform at ScotiabankMarch 7, 2025 | markets.businessinsider.comFY2027 Earnings Estimate for BPMC Issued By Zacks ResearchBlueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Investment analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for Blueprint Medicines in a research note issued on Wednesday, March 5th. Zacks Research analyst A. Chakraborty expects that the biotechnology companMarch 7, 2025 | marketbeat.comPrincipal Financial Group Inc. Increases Stake in Blueprint Medicines Co. (NASDAQ:BPMC)Principal Financial Group Inc. raised its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 46.6% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 16,183 shares of the biotechnology company's stock after purchasing an adMarch 6, 2025 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Insider Ariel Hurley Sells 3,203 SharesBlueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) insider Ariel Hurley sold 3,203 shares of Blueprint Medicines stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $92.62, for a total value of $296,661.86. Following the completion of the sale, the insider now directly owns 18,270 shares in the company, valued at $1,692,167.40. This represents a 14.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.March 5, 2025 | marketbeat.comInsider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) Insider Sells 3,203 Shares of StockMarch 5, 2025 | insidertrades.comBlueprint Medicines (NASDAQ:BPMC) Downgraded to Sell Rating by StockNews.comStockNews.com downgraded shares of Blueprint Medicines from a "hold" rating to a "sell" rating in a report on Monday.March 4, 2025 | marketbeat.comNBW Capital LLC Has $3.83 Million Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)NBW Capital LLC lifted its holdings in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 25.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 43,886 shares of the biotechnology company's stock after purchasing an additional 8,821 shares during the quarMarch 4, 2025 | marketbeat.comFisher Asset Management LLC Sells 12,310 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)Fisher Asset Management LLC cut its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 3.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 323,040 shares of the biotechnology companyMarch 3, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Pharvaris (PHVS) and Blueprint Medicines (BPMC)March 3, 2025 | markets.businessinsider.comBlueprint Medicines' (BPMC) Outperform Rating Reiterated at WedbushWedbush reiterated an "outperform" rating and set a $128.00 target price on shares of Blueprint Medicines in a research note on Friday.March 1, 2025 | marketbeat.comBlueprint Medicines' SWOT analysis: stock outlook amid Ayvakit's growthMarch 1, 2025 | uk.investing.comBlueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint CongressFebruary 28, 2025 | prnewswire.com Remove Ads Get Blueprint Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter. Email Address BPMC Media Mentions By Week BPMC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BPMC News Sentiment▼0.970.62▲Average Medical News Sentiment BPMC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BPMC Articles This Week▼177▲BPMC Articles Average Week Remove Ads Get Blueprint Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BNTX News Today TEVA News Today SMMT News Today ITCI News Today MRNA News Today GMAB News Today RDY News Today VTRS News Today ASND News Today PCVX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BPMC) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Blueprint Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
